Anti-TNF's for postoperative recurrence in Crohn's disease: The if's and how's

D. Sorrentino, A. Paviotti, G. Fiorino

Research output: Contribution to journalArticle

Abstract

Recurrence of Crohn's disease (CD) is extremely frequent after surgery and its prevention remains a fundamental problem in the medical management of these patients. As of today, none of the medications traditionally used to treat the spontaneous disease (i.e. mesalamine, steroids, immunosuppressives and antibiotics) has shown a clear benefit. Recent data, coming from our center and from a small RCT do indicate that infliximab is extremely effective in preventing this complication in the large majority of patients. While additional, larger studies may be desirable, the strength and consistency of the available data suggest that future trials may merely confirm these observations. A number of issues however remain to be solved and include the long term strategy in patients treated for years with infliximab, whether treating early endoscopic lesions may be as effective as preventing them and whether immuno-soppressives should be used together with infliximab. A thorough understanding of the mechanisms by which infliximab appears so effective in the postoperative setting may provide us with essential information regarding patients' management and, ultimately, highlight the molecular mechanisms at the very basis of Crohn's disease.

Original languageEnglish
Pages (from-to)219-226
Number of pages8
JournalCurrent Drug Targets
Volume11
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Crohn Disease
Recurrence
Mesalamine
Immunosuppressive Agents
Surgery
Steroids
Anti-Bacterial Agents
Infliximab

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Anti-TNF's for postoperative recurrence in Crohn's disease : The if's and how's. / Sorrentino, D.; Paviotti, A.; Fiorino, G.

In: Current Drug Targets, Vol. 11, No. 2, 02.2010, p. 219-226.

Research output: Contribution to journalArticle

@article{b4c65d5ddeff409bbd1d7e4a5b21a7b3,
title = "Anti-TNF's for postoperative recurrence in Crohn's disease: The if's and how's",
abstract = "Recurrence of Crohn's disease (CD) is extremely frequent after surgery and its prevention remains a fundamental problem in the medical management of these patients. As of today, none of the medications traditionally used to treat the spontaneous disease (i.e. mesalamine, steroids, immunosuppressives and antibiotics) has shown a clear benefit. Recent data, coming from our center and from a small RCT do indicate that infliximab is extremely effective in preventing this complication in the large majority of patients. While additional, larger studies may be desirable, the strength and consistency of the available data suggest that future trials may merely confirm these observations. A number of issues however remain to be solved and include the long term strategy in patients treated for years with infliximab, whether treating early endoscopic lesions may be as effective as preventing them and whether immuno-soppressives should be used together with infliximab. A thorough understanding of the mechanisms by which infliximab appears so effective in the postoperative setting may provide us with essential information regarding patients' management and, ultimately, highlight the molecular mechanisms at the very basis of Crohn's disease.",
author = "D. Sorrentino and A. Paviotti and G. Fiorino",
year = "2010",
month = "2",
doi = "10.2174/138945010790309920",
language = "English",
volume = "11",
pages = "219--226",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Anti-TNF's for postoperative recurrence in Crohn's disease

T2 - The if's and how's

AU - Sorrentino, D.

AU - Paviotti, A.

AU - Fiorino, G.

PY - 2010/2

Y1 - 2010/2

N2 - Recurrence of Crohn's disease (CD) is extremely frequent after surgery and its prevention remains a fundamental problem in the medical management of these patients. As of today, none of the medications traditionally used to treat the spontaneous disease (i.e. mesalamine, steroids, immunosuppressives and antibiotics) has shown a clear benefit. Recent data, coming from our center and from a small RCT do indicate that infliximab is extremely effective in preventing this complication in the large majority of patients. While additional, larger studies may be desirable, the strength and consistency of the available data suggest that future trials may merely confirm these observations. A number of issues however remain to be solved and include the long term strategy in patients treated for years with infliximab, whether treating early endoscopic lesions may be as effective as preventing them and whether immuno-soppressives should be used together with infliximab. A thorough understanding of the mechanisms by which infliximab appears so effective in the postoperative setting may provide us with essential information regarding patients' management and, ultimately, highlight the molecular mechanisms at the very basis of Crohn's disease.

AB - Recurrence of Crohn's disease (CD) is extremely frequent after surgery and its prevention remains a fundamental problem in the medical management of these patients. As of today, none of the medications traditionally used to treat the spontaneous disease (i.e. mesalamine, steroids, immunosuppressives and antibiotics) has shown a clear benefit. Recent data, coming from our center and from a small RCT do indicate that infliximab is extremely effective in preventing this complication in the large majority of patients. While additional, larger studies may be desirable, the strength and consistency of the available data suggest that future trials may merely confirm these observations. A number of issues however remain to be solved and include the long term strategy in patients treated for years with infliximab, whether treating early endoscopic lesions may be as effective as preventing them and whether immuno-soppressives should be used together with infliximab. A thorough understanding of the mechanisms by which infliximab appears so effective in the postoperative setting may provide us with essential information regarding patients' management and, ultimately, highlight the molecular mechanisms at the very basis of Crohn's disease.

UR - http://www.scopus.com/inward/record.url?scp=84876457850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876457850&partnerID=8YFLogxK

U2 - 10.2174/138945010790309920

DO - 10.2174/138945010790309920

M3 - Article

C2 - 20210769

AN - SCOPUS:84876457850

VL - 11

SP - 219

EP - 226

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 2

ER -